Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Myasthenia Gravis.

Michael Graves1, Jonathan S. Katz

  • 1Neurology Department, Palo Alto Veteran's Administration Hospital, 3801 Miranda Avenue, Palo Alto, CA 94304, USA. jskatz@stanford.edu

Current Treatment Options in Neurology
|February 5, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effectiveness of a leadership conference for chief residents in dermatology.

Clinics in dermatology·2023
Same author

Travel-Related Behaviors and Health Outcomes of Adolescents Compared with Adults on Short-Term International Service Missions.

The American journal of tropical medicine and hygiene·2021
Same author

Microbiome and Antimicrobial Resistance Gene Dynamics in International Travelers.

Emerging infectious diseases·2019
Same author

Fecal Host Transcriptomics for Non-Invasive Human Mucosal Immune Profiling: Proof of Concept in <i>Clostridium Difficile</i> Infection.

Pathogens & immunity·2018
Same author

Dried Blood Spots for Measuring Vibrio cholerae-specific Immune Responses.

PLoS neglected tropical diseases·2018
Same author

Successful Treatment of Chronic Venous Ulcers With a 1,320-nm Endovenous Laser Combined With Other Minimally Invasive Venous Procedures.

Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]·2016
Same journal

Visual Impairment and Driving in Older Adults: A Narrative Review.

Current treatment options in neurology·2026
Same journal

Non-Cognitive Symptoms in Alzheimer's Disease and Their Likely Impact on Patient Outcomes. A Scoping Review.

Current treatment options in neurology·2026
Same journal

Update on the Treatment of Autonomic Disorders.

Current treatment options in neurology·2025
Same journal

Primary Progressive Aphasia Treatment: Current Treatment Options in Neurology Article Topic: Management of Primary Progressive Aphasia.

Current treatment options in neurology·2025
Same journal

Emerging Principles for Treating Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD).

Current treatment options in neurology·2025
Same journal

Diagnosis and Management of Progressive Corticobasal Syndrome.

Current treatment options in neurology·2025
See all related articles

Myasthenia gravis, a neuromuscular disorder causing muscle weakness, has various treatments. Physicians must weigh efficacy, side effects, and costs for optimal patient management.

Area of Science:

  • Neurology
  • Immunology

Background:

  • Myasthenia gravis is a neuromuscular transmission disorder characterized by variable skeletal muscle weakness.
  • It affects multiple muscle groups, including ocular, bulbar, facial, limb, and neck muscles.

Purpose of the Study:

  • To review the evidence basis for myasthenia gravis therapies.
  • To discuss the trade-offs between treatment efficacy, timing, side effects, costs, and benefits.

Main Methods:

  • Review of current therapeutic agents influencing neuromuscular junction function and immune response.
  • Evaluation of treatments such as thymectomy, plasma exchange, and intravenous immunoglobulin.
  • Consideration of the onset of action for rapid patient improvement, especially in intensive care settings.

Related Experiment Videos

Main Results:

  • A range of therapies exist for myasthenia gravis, each with distinct efficacy, timing, and side effect profiles.
  • Plasma exchange is effective for rapid improvement in myasthenic crisis.
  • High-dose intravenous immunoglobulin is gaining popularity, with its role still under study.

Conclusions:

  • Effective management of myasthenia gravis requires a thorough understanding of available treatments and their evidence base.
  • The choice of therapy should balance disease control with potential costs and benefits.
  • Rapid-onset treatments are crucial for patients requiring intensive care or respiratory support.